Database Query Results : , , BIM

BIM, BIM protein (BCL-2 Interacting Mediator of cell death): Click to Expand ⟱
Source:
Type:
A pro-apoptotic protein that plays a crucial role in regulating cell death, particularly in the context of cancer. BIM is a member of the BCL-2 family of proteins, which are key regulators of apoptosis (programmed cell death).
BIM cancer is characterized by the overexpression of the BIM protein, which is a pro-apoptotic protein that promotes cell death.
BIM protein has been shown to have both tumor-suppressive and tumor-promoting roles, depending on the context.
High BIM expression: Melanoma, lung, breast, colorectal.
Low BIM expression: Leukemia, Lymphoma, Prostate
The expression of BIM can serve as a prognostic marker in several cancers. Higher levels of BIM are often associated with increased apoptosis and better treatment responses, while lower levels may indicate resistance to therapy and poorer outcomes.


Scientific Papers found: Click to Expand⟱
266- ALA,    Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death
- in-vitro, Ovarian, IGROV1
Mcl-1↓, Bcl-xL↓, BIM↑, ROS↑,
1537- Api,    Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer
- Review, PC, NA
TumCP↓, TumCCA↑, Apoptosis↑, MMPs↓, Akt↓, *BioAv↑, *BioAv↓, Half-Life∅, Hif1a↓, GLUT1↓, VEGF↓, ChemoSen↑, ROS↑, Bcl-2↓, Bcl-xL↓, BAX↑, BIM↑,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, eff↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
3156- Ash,    Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug
- Review, Var, NA
MAPK↑, p38↑, BAX↑, BIM↑, CHOP↑, ROS↑, DR5↑, Apoptosis↑, Ferroptosis↑, GPx4↓, BioAv↝, HSP90↓, RET↓, E6↓, E7↓, Akt↓, cMET↓, Glycolysis↓, TCA↓, NOTCH1↓, STAT3↓, AP-1↓, PI3K↓, eIF2α↓, HO-1↑, TumCCA↑, CDK1↓, *hepatoP↑, *GSH↑, *NRF2↑, Wnt↓, EMT↓, uPA↓, CSCs↓, Nanog↓, SOX2↓, CD44↓, lactateProd↓, Iron↑, NF-kB↓,
1517- CAP,    Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1)
- in-vitro, Bladder, TSGH8301 - in-vitro, CRC, T24
ENOX2↓, TumCCA↑, ERK↓, p‑FAK↓, p‑pax↓, TumCMig↓, EMT↓, SIRT1↓, Dose∅, ROS↑, MMP↓, Bcl-2↓, Bak↑, cl‑PARP↑, Casp3↑, SIRT1↓, ac‑P53↑, BIM↑, p‑RB1↓, cycD1/CCND1↓, Dose∅, β-catenin/ZEB1↓, N-cadherin↓, E-cadherin↑,
4826- CUR,    The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management
- Review, Var, NA
*antiOx↑, *Inflam↑, *ROS↓, Apoptosis↑, TumCP↓, BioAv↓, Half-Life↓, eff↑, TumCCA↑, BAX↑, Bak↑, PUMA↑, BIM↑, NOXA↑, TRAIL↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, cMyc↓, Casp↑, NF-kB↓, STAT3↓, AP-1↓, angioG↓, TumMeta↑, VEGF↓, MMPs↓, DNMTs↓, HDAC↓, ROS↑,
462- CUR,    Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress
- in-vitro, Pca, PC3
Bcl-2↓, MMP↓, cl‑Casp3↑, BAX↑, BIM↑, p‑PARP↑, PUMA↑, p‑P53↑, ROS↑, p‑ERK↑, p‑eIF2α↑, CHOP↑, ATF4↑,
1860- dietFMD,  Chemo,    Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
- in-vitro, BC, SUM159 - in-vitro, BC, 4T1
PI3K↑, Akt↑, mTOR↑, CDK4↑, CDK6↑, hyperG↓, TumCG↓, TumVol↓, Casp3↑, BG↓, eff↑, eff∅, PKA↓, KLF5↓, p‑GSK‐3β↑, Nanog↓, OCT4↓, KLF2↓, eff↑, ROS↑, BIM↑, ASK1↑, PI3K↑, Akt↑, mTOR↑, CDK1↓, CDK4↑, CDK6↑, eff↑,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycA1/CCNA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
2849- FIS,    Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells
- in-vitro, Melanoma, U266
TumCD↑, TumCCA↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, p‑Akt↓, p‑mTOR↓, ROS↑, eff↓,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,
2832- FIS,    Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
- Review, Var, NA
MMP↓, mtDam↑, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, Bak↑, BIM↑, Bcl-xL↓, Bcl-2↓, P53↑, ROS↑, AMPK↑, Casp9↑, Casp3↑, BID↑, AIF↑, Akt↓, mTOR↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, TumMeta↓, uPA↓, E-cadherin↑, Vim↓, EMT↓, Twist↓, DNAdam↑, ROS↓, COX2↓, PGE2↓, HSF1↓, cFos↓, cJun↓, AP-1↓, Mcl-1↓, NF-kB↓, IRE1↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MMP2↓, MMP9↓, TCF-4↓, MMP7↓, RadioS↑, TOP1↓, TOP2↓,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
87- QC,    Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ROS⇅, BAX↑, PUMA⇅, β-catenin/ZEB1↓, Shc↓, TAp63α↑, MAPK↑, p‑p42↑, p‑p44↑, BIM↑,
3061- RES,    The Anticancer Effects of Resveratrol: Modulation of Transcription Factors
- Review, Var, NA
AhR↓, NRF2↑, *NQO1↑, *HO-1↑, *GSH↑, P53↑, Cyt‑c↑, Diablo↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, FOXO↑, p‑PI3K↓, p‑Akt↓, BIM↑, DR4↑, DR5↑, p27↑, cycD1/CCND1↓, SIRT1↑, NF-kB↓, ATF3↑,
4501- Se,    Mechanisms of the Cytotoxic Effect of Selenium Nanoparticles in Different Human Cancer Cell Lines
- in-vitro, GBM, A172 - in-vitro, Colon, Caco-2 - in-vitro, Pca, DU145 - in-vitro, BC, MCF-7 - in-vitro, Nor, L929
*BioAv↑, selectivity↑, AntiCan↑, Apoptosis↑, CHOP↑, GADD34↑, BIM↑, PUMA↑, Ca+2↝,
1002- Sel,  Osi,  Adag,    Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
- in-vitro, Lung, H1975 - in-vitro, Lung, H385
Apoptosis↑, Ferroptosis↑, DNMT1↓, TET1↑, TumCCA↑, cl‑PARP↑, cl‑Casp3↑, Cyt‑c↑, BIM↑, NOXA↑, Apoptosis↑, ROS↑, ER Stress↑, UPR↑,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 19

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

ATF3↑, 1,   ENOX2↓, 1,   Ferroptosis↑, 2,   GPx4↓, 1,   GSH↓, 1,   GSH↑, 1,   GSTs↓, 1,   HO-1↑, 3,   hyperG↓, 1,   Iron↑, 1,   lipid-P↓, 1,   MDA↑, 1,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 2,   ROS↓, 1,   ROS↑, 14,   ROS⇅, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,   TrxR↓, 1,  

Metal & Cofactor Biology

KLF5↓, 1,  

Mitochondria & Bioenergetics

AIF↑, 2,   CDC2↓, 1,   CDC25↓, 1,   EGF↓, 1,   MEK↓, 3,   MMP↓, 8,   mtDam↑, 1,   p‑p42↑, 1,   Raf↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis

ACC↑, 3,   AMPK↑, 3,   cMyc↓, 3,   Glycolysis↓, 2,   HK2↓, 1,   lactateProd↓, 1,   SIRT1↓, 2,   SIRT1↑, 1,   TCA↓, 1,  

Cell Death

AhR↓, 1,   Akt↓, 8,   Akt↑, 2,   p‑Akt↓, 2,   APAF1↑, 1,   Apoptosis↑, 8,   ASK1↑, 1,   BAD↑, 3,   Bak↑, 4,   BAX↑, 12,   Bcl-2↓, 13,   Bcl-xL↓, 7,   BID↑, 1,   BIM↓, 1,   BIM↑, 18,   Casp↑, 3,   Casp3↑, 10,   cl‑Casp3↑, 2,   Casp7↑, 1,   Casp8↑, 2,   cl‑Casp8↑, 1,   Casp9↑, 3,   Cyt‑c↑, 7,   Diablo↑, 4,   DR4↑, 2,   DR5↑, 4,   Fas↑, 1,   Ferroptosis↑, 2,   GADD34↑, 1,   MAPK↓, 2,   MAPK↑, 2,   Mcl-1↓, 6,   MDM2↓, 1,   MLKL↑, 1,   p‑MLKL↓, 1,   Myc↓, 1,   Necroptosis↑, 1,   NOXA↑, 3,   p27↑, 2,   p38↓, 1,   p38↑, 1,   PUMA↑, 3,   PUMA⇅, 1,   survivin↓, 4,   TRAIL↑, 2,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction

p‑HER2/EBBR2↓, 1,   RET↓, 1,   Sp1/3/4↓, 2,  

Transcription & Epigenetics

cJun↓, 3,   HATs↑, 1,   Shc↓, 1,   tumCV↓, 2,  

Protein Folding & ER Stress

CHOP↑, 5,   eIF2α↓, 1,   p‑eIF2α↑, 2,   ER Stress↑, 2,   GRP78/BiP↑, 1,   HSF1↓, 1,   HSP27↓, 1,   HSP70/HSPA5↓, 2,   HSP90↓, 1,   IRE1↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes

LC3B↑, 1,   LC3II↑, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair

DNAdam↑, 4,   DNMT1↓, 1,   DNMTs↓, 1,   P53↑, 5,   p‑P53↑, 2,   ac‑P53↑, 1,   p‑PARP↑, 2,   cl‑PARP↑, 5,   PCNA↓, 2,  

Cell Cycle & Senescence

CDK1↓, 3,   CDK2↓, 4,   CDK4↓, 4,   CDK4↑, 2,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 7,   cycE/CCNE↓, 1,   P21↑, 3,   RB1↓, 1,   p‑RB1↓, 1,   Securin↓, 1,   TAp63α↑, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State

CD44↓, 1,   cFos↓, 4,   cMET↓, 2,   CSCs↓, 1,   EMT↓, 6,   ERK↓, 4,   p‑ERK↓, 1,   p‑ERK↑, 1,   FOXO↑, 1,   FOXO3↑, 1,   p‑FOXO3↓, 1,   p‑GSK‐3β↑, 1,   HDAC↓, 2,   mTOR↓, 5,   mTOR↑, 2,   p‑mTOR↓, 1,   Nanog↓, 3,   NOTCH1↓, 1,   OCT4↓, 2,   PI3K↓, 4,   PI3K↑, 2,   p‑PI3K↓, 1,   SOX2↓, 2,   STAT3↓, 3,   TCF↑, 1,   TCF-4↓, 1,   TOP1↓, 1,   TOP2↓, 2,   TumCG↓, 3,   TumCG↑, 1,   Wnt↓, 4,  

Migration

AP-1↓, 3,   Ca+2↝, 1,   CD31↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 4,   p‑FAK↓, 1,   Fibronectin↓, 2,   Ki-67↓, 1,   KLF2↓, 1,   MET↓, 1,   MMP1↓, 1,   MMP2↓, 3,   MMP3↓, 1,   MMP7↓, 2,   MMP9↓, 3,   MMPs↓, 3,   N-cadherin↓, 4,   p‑p44↑, 1,   p‑pax↓, 1,   PKA↓, 1,   RIP3↑, 1,   p‑RIP3↑, 1,   Slug↓, 1,   Snail↓, 3,   TET1↑, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 4,   TumMeta↓, 4,   TumMeta↑, 1,   Twist↓, 3,   uPA↓, 5,   Vim↓, 4,   Zeb1↓, 1,   β-catenin/ZEB1↓, 5,  

Angiogenesis & Vasculature

angioG↓, 5,   ATF4↓, 1,   ATF4↑, 3,   EGFR↓, 3,   eNOS↓, 1,   Hif1a↓, 2,   VEGF↓, 4,   VEGFR2↓, 1,  

Barriers & Transport

GLUT1↓, 1,  

Immune & Inflammatory Signaling

COX2↓, 3,   IFN-γ↑, 1,   IKKα↓, 1,   IL10↓, 1,   IL2↑, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   JAK1↓, 1,   JAK2↓, 1,   MDSCs↓, 1,   NF-kB↓, 8,   NF-kB↑, 1,   p65↓, 1,   PGE2↓, 2,  

Hormonal & Nuclear Receptors

CDK6↓, 2,   CDK6↑, 2,  

Drug Metabolism & Resistance

BioAv↓, 1,   BioAv↝, 1,   ChemoSen↑, 4,   Dose∅, 3,   eff↓, 3,   eff↑, 9,   eff∅, 1,   Half-Life↓, 1,   Half-Life∅, 1,   RadioS↑, 2,   selectivity↓, 1,   selectivity↑, 3,  

Clinical Biomarkers

BG↓, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 3,   p‑HER2/EBBR2↓, 1,   IL6↓, 1,   Ki-67↓, 1,   Myc↓, 1,  

Functional Outcomes

AntiCan↑, 1,   cardioP↑, 2,   chemoP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 2,  
Total Targets: 254

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 2,   GSH↑, 3,   HO-1↑, 1,   lipid-P↓, 1,   NQO1↑, 1,   NRF2↑, 2,   ROS↓, 1,  

Immune & Inflammatory Signaling

Inflam↑, 1,  

Drug Metabolism & Resistance

BioAv↓, 2,   BioAv↑, 2,  

Functional Outcomes

hepatoP↑, 2,   neuroP↑, 1,  
Total Targets: 12

Scientific Paper Hit Count for: BIM, BIM protein (BCL-2 Interacting Mediator of cell death)
4 Fisetin
2 Apigenin (mainly Parsley)
2 Curcumin
1 Alpha-Lipoic-Acid
1 Metformin
1 Ashwagandha(Withaferin A)
1 Capsaicin
1 diet FMD Fasting Mimicking Diet
1 Chemotherapy
1 Piperlongumine
1 Quercetin
1 Resveratrol
1 Selenium
1 Selenite
1 Osimertinib
1 Adagrasib
1 Sulforaphane (mainly Broccoli)
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:483  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page